Related Experiment Video
Updated: Jul 3, 2026
09:40
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
[Immune-mediated hemolytic anemia under oxaliplatin]
F Gundling1, M Tiller, M Fuchs
1Second Department of Medicine, Bogenhausen Academic Teaching Hospital, Technical University of Munich. Felix.Gundling@gmx.de
Zeitschrift Fur Gastroenterologie
|July 12, 2008
Summary
Oxaliplatin chemotherapy can rarely cause autoimmune hemolytic anemia (AIHA), a serious condition. Early diagnosis with a direct Coombs test is crucial to manage this rare oxaliplatin side effect.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Oxaliplatin is a common chemotherapy agent used for colorectal cancer.
- Autoimmune hemolytic anemia (AIHA) is a rare but serious adverse effect of oxaliplatin treatment.
Observation:
- A 68-year-old patient receiving oxaliplatin-based chemotherapy (FUFOX) for metastatic adenocarcinoma developed jaundice and dyspnea.
- Laboratory tests revealed hemolytic anemia with thrombocytopenia and neutropenia, progressing rapidly.
- A positive direct Coombs test confirmed oxaliplatin-mediated AIHA.
Findings:
- Pulse steroid therapy and transfusions normalized blood counts.
- Chemotherapy was switched to an oxaliplatin-free regimen due to immune pancytopenia and tumor progression.
- Re-exposure to oxaliplatin can lead to more severe hemolysis.
Implications:
- Prompt diagnosis of oxaliplatin-induced AIHA is essential.
- The direct Coombs test is the key diagnostic marker for AIHA.
- Discontinuation of oxaliplatin and appropriate management are vital for patient outcomes.
